Invega Sustenna (generic name: paliperidone palmitate) is a long-acting antipsychotic medication used primarily to treat schizophrenia and schizoaffective disorder. It belongs to the class of atypical antipsychotics and works by modulating dopamine and serotonin activity in the brain to help manage symptoms of psychosis. Unlike daily oral medications, Invega Sustenna is administered as an extended-release intramuscular injection, providing continuous symptom control over time.
Paliperidone, the active ingredient, is the primary metabolite of risperidone and exerts its effects by blocking dopamine D2 and serotonin 5-HT2A receptors. This mechanism helps reduce hallucinations, delusions, and disorganized thinking while improving mood stability. The long-acting nature of Invega Sustenna ensures a steady drug concentration in the body, reducing the risk of symptom relapse in patients who may struggle with daily medication adherence.
Invega Sustenna is FDA-approved for the treatment of schizophrenia in adults, a mental health disorder characterized by disruptions in thought processes, emotional responsiveness, and social interactions. It is also indicated for schizoaffective disorder, a condition that combines symptoms of schizophrenia with mood disturbances such as depression or mania. The medication helps manage both positive symptoms (such as hallucinations and delusions) and negative symptoms (such as social withdrawal and reduced emotional expression).
The extended-release formulation eliminates the need for daily dosing, making it a preferred option for individuals requiring consistent symptom control. Patients receiving Invega Sustenna typically begin with an initiation phase, followed by monthly maintenance injections. This approach helps maintain therapeutic drug levels without the need for frequent adjustments.
While Invega Sustenna is highly effective, it should be used under medical supervision, as it may have side effects and specific contraindications. Patients receiving this medication should be monitored regularly to assess their response and manage potential adverse effects.
Read further information on schizophrenia and its treatment here.
Dosage and Administration
Invega Sustenna is administered as an intramuscular injection by a healthcare professional. The standard regimen begins with an initiation phase, typically involving two doses administered in the first week (on days 1 and 8), followed by maintenance injections given once monthly. The first dose is usually given in the deltoid muscle, and subsequent doses may be administered in either the deltoid or gluteal muscle.
The dosing strength is individualized based on the patient’s clinical needs and prior treatment history. Once the maintenance dose is established, adhering to the monthly injection schedule is important to ensure continuous symptom management. If a scheduled dose is missed, a healthcare provider will determine the best approach to resume treatment.
Patients transitioning from oral antipsychotics may require a gradual adjustment period. Since Invega Sustenna is a long-acting medication, sudden discontinuation of oral therapy should be done under medical supervision.
Storage Guidelines
Invega Sustenna should be stored at room temperature, between 20°C to 25°C (68°F to 77°F). The medication should remain in its original packaging until use to protect it from light and moisture. For more information, read our article on drug storage.
Common Questions About Invega Sustenna
Does Invega Sustenna cause weight gain?
Weight gain is a potential side effect of Invega Sustenna, particularly with long-term use. Lifestyle modifications such as diet and exercise can help manage this effect.
Can I drink alcohol while taking Invega Sustenna?
Alcohol should be avoided, as it can increase drowsiness and dizziness associated with the medication.
How long does Invega Sustenna take to work?
Symptom improvement may be noticed within a few days, but full effects may take several weeks as the medication builds up in the system.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.Â
Read the information leaflet that comes with the medication.
If a sudden allergic reaction (anaphylaxis) occurs after taking Invega Sustenna, with symptoms like swelling of the face, tongue, or throat making it difficult to breathe or swallow, or there is wheezing, hives, rash, blistering, or peeling of the skin, call a doctor or 911 right away, or go to an emergency room immediately.
Most people who use Invega Sustenna do not experience any adverse side effects. Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.
Some of the side effects that have been reported include:
- Injection site reactions (pain, redness, swelling)
- Drowsiness or fatigue
- Weight gain
- Increased prolactin levels (may cause breast enlargement, lactation, or menstrual changes)
- Dizziness
- Constipation
- Increased heart rate.
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
Invega Sustenna is primarily approved for the treatment of schizophrenia and schizoaffective disorder. Schizophrenia is a chronic mental health disorder that affects perception, thought processes, and emotional regulation. Symptoms may include hallucinations, delusions, disorganized thinking, social withdrawal, and cognitive impairment. The medication helps manage both acute and long-term symptoms, improving overall functioning and reducing the risk of relapse.
Schizoaffective disorder is a related condition that combines symptoms of schizophrenia with mood disturbances, such as depression or mania. Invega Sustenna is used to stabilize mood fluctuations and psychotic symptoms, helping individuals maintain emotional and cognitive balance.
Some healthcare providers may prescribe Invega Sustenna off-label for other conditions, such as bipolar disorder, when extended-release antipsychotic therapy is beneficial. However, off-label use should be carefully evaluated by a healthcare professional.